Enovis (ENOV) Income from Non-Controlling Interests (2012 - 2026)
Enovis' (ENOV) quarterly Income from Non-Controlling Interests came in at $154000.0 in Q3 2026, down 19.37% year-over-year from $191000.0 in Q3 2025, and down 50.96% quarter-over-quarter from $314000.0 in Q2 2026.
Powered by 
Analysis
Enovis (ENOV) Income from Non-Controlling Interests (2012 - 2026) Analysis & Trends
Enovis (ENOV) has reported Income from Non-Controlling Interests for 15 consecutive years, with $154000.0 the latest figure, recorded in Q3 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 19.37% year-over-year to $154000.0 in Q3 2026; TTM through Jul 2026 was $836000.0, a 1.42% decrease from a year earlier, with the FY2025 full-year figure at $820000.0, up 20.77% from the prior year.
- Income from Non-Controlling Interests was $154000.0 for Q3 2026 at Enovis, down from $314000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $966000.0 in Q2 2022 and troughed at $34000.0 in Q4 2022.
- A 5-year average of $209055.6 and a median of $155500.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests slumped 97.09% in 2022 and jumped 547.5% in 2024, its largest moves.
- Over 5 years, Income from Non-Controlling Interests stood at $34000.0 in 2022, then jumped by 241.18% to $116000.0 in 2023, then grew by 18.1% to $137000.0 in 2024, then fell by 1.46% to $135000.0 in 2025, then advanced by 14.07% to $154000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $154000.0 (Q3 2026), $314000.0 (Q2 2026), and $135000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.70 Bn | 177.10 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 126.82 Bn | 121.60 Bn | 1.96 Bn | 6.60 Mn |
| 3 | Medtronic | 117.93 Bn | 109.11 Bn | 6.34 Bn | 9.00 Mn |
| 4 | Stryker | 104.83 Bn | 101.36 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 64.79 Bn | 64.25 Bn | 3.85 Bn | -2.00 Mn |
| 6 | Edwards Lifesciences | 49.83 Bn | 45.58 Bn | 1.35 Bn | -500,000.00 |
| 7 | Alcon | 32.99 Bn | 31.53 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.14 Bn | 30.20 Bn | 830.00 Mn | - |
| 9 | Steris | 20.75 Bn | 20.27 Bn | 684.20 Mn | 900,000.00 |
| 10 | Enovis | 1.07 Bn | 1.06 Bn | 359.25 Mn | 154,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 154,000.00 |
| Apr 3, 2026 | 314,000.00 |
| Dec 31, 2025 | 135,000.00 |
| Oct 3, 2025 | 233,000.00 |
| Jul 4, 2025 | 191,000.00 |
| Apr 4, 2025 | 261,000.00 |
| Dec 31, 2024 | 137,000.00 |
| Sep 27, 2024 | 259,000.00 |
| Jun 28, 2024 | 126,000.00 |
| Mar 29, 2024 | 157,000.00 |
| Dec 31, 2023 | 116,000.00 |
| Sep 29, 2023 | 40,000.00 |
| Jun 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 192,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Sep 30, 2022 | 136,000.00 |
| Jul 1, 2022 | 130,000.00 |
| Apr 1, 2022 | 966,000.00 |
| Dec 31, 2021 | 1.17 Mn |
| Oct 1, 2021 | 818,000.00 |